Dr. Pal on the Background of the COSMIC-021 Trial in ​Urothelial Cancer

Publication
Video
Supplements And Featured PublicationsASCO 2020: Update on Genitourinary Cancers
Volume 1
Issue 1

Sumanta K. Pal, MD, discusses the background of the COSMIC-021 trial in urothelial cancer.

Sumanta K. Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, medical oncologist, City of Hope, discusses the background of the COSMIC-021 trial in urothelial cancer.

COSMIC-021 is an exciting multicenter, phase 1b study that was designed to enroll patients with genitourinary cancers, says Pal. Investigators began with 3 cohorts of patients ​with bladder cancer, kidney cancer, and prostate cancer. ​However, the ​trial was expanded ​to over 20 cohorts ​of patients.

Patients enrolled in the trial received a combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq).

In cohort ​2, investigators looked at a total of 30 patients ​with urothelial carcinoma who had received prior platinum-based chemotherapy, says Pal. Moreover, investigators found that 43%* of patients received greater than or equal to 2 ​or more prior lines of ​anti-cancer therapy. The fact that these patients were heavily pretreated should be taken into consideration when comparing the results from cohort 2 of the trial with other data sets regarding combinations of immunotherapy and targeted therapy, concludes Pal.

Related Videos
Martin H. Voss, MD, an expert on renal cell carcinoma
Laurence Albigès, MD, PhD, an expert on renal cell carcinoma
Nikhil A. Gopal, MD
Nikhil A. Gopal, MD
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma